As the world responds to the COVID-19 pandemic, robust evidence in priority populations is urgently needed to guide clinical care and public health policy. However, there are gaps in knowledge regarding the impact of SARS-CoV-2 on pregnant persons and their infants. Moreover, the maternal-newborn population requires unique consideration and care due to increased vulnerability to respiratory infections and to medical interventions used to treat infection. Access to maternal and infant biological samples is therefore imperative for gaining a more comprehensive understanding of the burden of SARS-CoV-2 on a pregnant population.

Study Purpose

The Rapid Response Maternal-Infant Clinical and Biospecimen Access Platform, or Biorepository Study, is a project aimed at better understanding the burden of COVID-19 on pregnancy. To do this, we have established a Biorepository of data and samples for future studies related to COVID-19 in pregnant populations. Recruitment of 60 pregnant persons diagnosed with COVID-19 at any point in pregnancy is now underway.

Study Eligibility
In order to be eligible to participate, you must:
1. Be a pregnant woman/individual
2. Be 16 years of age or older
3. Have a confirmed diagnosis of COVID-19 at any point during your pregnancy
4. Registered to deliver at BC Women’s Hospital
5. Agree to the collection of samples described in the consenting process

All personal information will be kept confidential. If a potential candidate declines to provide consent, their information will be securely destroyed.

Please ask your doctor to submit a form on your behalf

For further information on how to enrol in this study and or to ask questions, please contact us via email at

The Biorepository is associated with CANCOVID-Preg and funded by the UBC Strategic Investment Fund and the Canadian Institutes of Health Research. The Biorepository is also registered with the Canadian Tissue Repository Network (